Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: CONRAD Clear all
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

NCT01687218
View directory record Official record
Conditions
HIV
Interventions
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older · Male only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Postcoital Testing of the SILCS Diaphragm

NCT00561613
View directory record Official record
Conditions
Contraceptive Device
Interventions
SILCS and lubricant, SILCS and spermicide
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2007 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% gel, Vaginal product
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Francisco, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

NCT04047420
View directory record Official record
Conditions
HIV Infections
Interventions
TAF/EVG Insert
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD Study of Oral F/TAF for HIV Prevention

NCT02904369
View directory record Official record
Conditions
HIV
Interventions
Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 28, 2026, 6:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Residence Time of Biomarkers of Semen Exposure

NCT00984555
View directory record Official record
Conditions
Semen Exposure
Interventions
Not listed
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of UC-781 Vaginal Microbicide

NCT00132444
View directory record Official record
Conditions
HIV Infections
Interventions
topical vaginal application of UC-781 gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel

NCT02309554
View directory record Official record
Conditions
Contraception
Interventions
SILCS diaphragm used with ContraGel, SILCS diaphragm used with 3% Nonoxynol-9, SILCS diaphragm
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

NCT01694407
View directory record Official record
Conditions
HIV
Interventions
Tenofovir (TFV) Alone Vaginal Tablet, Emtricitabine (FTC) Alone Vaginal Tablet, TFV and FTC Combined Vaginal Tablet, Placebo Vaginal Tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
The Bronx, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom

NCT01178840
View directory record Official record
Conditions
Birth Control
Interventions
WC then FC2, FC2 then WC
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue

NCT01347632
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Discharge
Interventions
Metronidazole
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbicide Safety and Acceptability in Young Men

NCT01283360
View directory record Official record
Conditions
High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions
HEC Placebo Gel, Tenofovir 1% Gel
Other · Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploratory Pharmacodynamic Study of Tenofovir-Based Products

NCT02722343
View directory record Official record
Conditions
HIV
Interventions
Tenofovir intravaginal ring, Truvada
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

NCT01232803
View directory record Official record
Conditions
Rectal Microbicides
Interventions
Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Male Hormonal Contraceptive Development-ACY-5

NCT00161447
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

NCT00561496
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2008 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

NCT04195776
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir Douche
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

NCT01768962
View directory record Official record
Conditions
HIV Prevention
Interventions
Once Daily Application of TFV RG 1% Gel - Vaginal, Once Daily Application of TFV RG 1% gel - Rectal
Drug
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 28, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04

NCT01989663
View directory record Official record
Conditions
HIV
Interventions
1% vaginally applied tenofovir gel, Tenofovir film- 10mg, Tenofovir Film-40 mg, HEC Placebo Gel, Placebo Vaginal Film
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 28, 2026, 6:49 PM EDT